Screener
SELLAS Life Sciences Group, Inc. SLS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by SELLAS Life Sciences Group, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001390478-26-000008
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $107,097 | $71,793 |
| Restricted cash and cash equivalents | 100 | 100 |
| Prepaid expenses and other current assets | 3,972 | 3,318 |
| Total current assets | 111,169 | 75,211 |
| Operating lease right-of-use assets | 839 | 963 |
| Goodwill | 1,914 | 1,914 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is SELLAS Life Sciences Group, Inc.'s cash & equivalents?
- SELLAS Life Sciences Group, Inc. (SLS) reported cash & equivalents of $107.1M in Q1 2026.
- How has SELLAS Life Sciences Group, Inc.'s cash & equivalents changed year-over-year?
- SELLAS Life Sciences Group, Inc.'s cash & equivalents increased by 277.1% year-over-year, from $28.4M to $107.1M.
- What is the long-term trend for SELLAS Life Sciences Group, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s cash & equivalents has grown at a 15.3% compound annual growth rate (CAGR), from $35.3M to $71.79M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about SELLAS Life Sciences Group, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude